EtiraRx is a series a startup based in United States. 2 investors tracked on Brouky Intelligence. Data sourced from Brouky Intelligence.
About
EtiraRx is a clinical-stage biopharmaceutical company developing a new class of cancer therapeutics that target the PI3K/AKT/mTOR pathway to induce cancer-specific cell death.
Stage
series-a
Investors
2
See full investor history, risk signals & comparable companies
Brouky tracks 15,000+ startups with funding rounds, risk analysis, and AI-powered investor matching.
Subscribe to Brouky